belantamab mafodotin   Click here for help

GtoPdb Ligand ID: 11117

Synonyms: belamaf [4] | belantamab mafodotin-blmf | Blenrep® | GSK-2857916 | GSK2857916
Approved drug Immunopharmacology Ligand
belantamab mafodotin is an approved drug (FDA & EMA (2020))
Compound class: Antibody
Comment: Belantamab mafodotin (GSK2857916) is a humanised BCMA-targeting antibody-drug conjugate that is in clinical development for multiple myeloma. Mafodotin is the cytotoxic, synthetic antineoplastic monomethyl auristatin F (MMAF; PubChem CID 56841603). Belantamab mafodotin is an IgG1 class antibody so, in addition to its delivery of a cytotoxin, it is predicted to exhibit lytic activity (through complement binding) and/or induce antibody-dependent cell cytotoxicity (ADCC). GlaxoSmithKline claim anti-BCMA ADCs in patent US9273141B2 [1]. SEQ IDs 55 and 63 from US9273141B2 match the full-length heavy chain and light chain sequences respectively, that were submitted to the WHO for the belantamab mafodotin INN.
Click here for help
Immunopharmacology Comments
Belantamab mafodotin (GSK2857916) targets a cytotoxic payload to abnormal immature plasma MM cells that express the B cell maturation antigen (BCMA: TNFRSF17). One notable side-effect of belantamab mafodotin that has not been observed with other multiple myeloma drugs is keratopathy (a corneal condition that causes dry eyes, blurry vision and potentially, severe vision loss) [5]. GlaxoSmithKline are advising using a risk evaluation and mitigation strategy to manage this adverse reaction, that includes eye examinations before each treatment cycle and reducing or delaying the next dose if appropriate.